Press releases
- Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
- Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Spyre Therapeutics Announces Grants of Inducement Awards
- Spyre Therapeutics Announces $180 Million Private Placement
- Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 40.28m |
Free float | 35.73m |
P/E (TTM) | -- |
Market cap | 1.52bn USD |
EPS (TTM) | -71.35 USD |
--
More ▼